Activation of the ATF2/CREB-PGC-1 alpha pathway by metformin leads to dopaminergic neuroprotection

作者：Kang Hojin; Khang Rin; Ham Sangwoo; Jeong Ga Ram; Kim Hyojung; Jo Minkyung; Lee Byoung Dae; Lee Yun Il; Jo Areum; Park ChiHu; Kim Hyein; Seo Jeongkon; Paek Sun Ha; Lee Yun Song; Choi Jeong Yun; Lee Yunjong; Shin Joo Ho^*

来源：Oncotarget, 2017, 8(30): 48603-48618.

DOI：10.18632/oncotarget.18122

• metformin
• dopaminergic
• Parkinson's disease
• PGC-1 alpha
• mitochondria
• Gerotarget

Progressive dopaminergic neurodegeneration is responsible for the canonical motor deficits in Parkinson's disease (PD). The widely prescribed anti-diabetic medicine metformin is effective in preventing neurodegeneration in animal models; however, despite the significant potential of metformin for treating PD, the therapeutic effects and molecular mechanisms underlying dopaminergic neuroprotection by metformin are largely unknown.
In this study, we found that metformin induced substantial proteomic changes, especially in metabolic and mitochondrial pathways in the substantia nigra (SN). Consistent with this data, metformin increased mitochondrial marker proteins in SH-SY5Y neuroblastoma cells. Mitochondrial protein expression by metformin was found to be brain region specific, with metformin increasing mitochondrial proteins in the SN and the striatum, but not the cortex. As a potential upstream regulator of mitochondria gene transcription by metformin, PGC-1 alpha promoter activity was stimulated by metformin via CREB and ATF2 pathways. PGC-1 alpha and phosphorylation of ATF2 and CREB by metformin were selectively increased in the SN and the striatum, but not the cortex. Finally, we showed that metformin protected dopaminergic neurons and improved dopamine-sensitive motor performance in an MPTP-induced PD animal model. Together these results suggest that the metformin-ATF2/CREB-PGC-1 alpha pathway might be promising therapeutic target for PD.

• 出版日期2017-7-25